Laboratory predictors of bleeding and the effect of platelet and RBC transfusions on bleeding outcomes in the PLADO trial

Blood

Volumn 130, Issue 10, 2017, Pages 1247-1258

  Uhl, Lynne ^a,b   Assmann, Susan F ^c   Hamza, Taye H ^c   Harrison, Ryan W ^d   Gernsheimer, Terry ^e,f,g   Slichter, Sherrill J ^e,f,g  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c NEW ENGLAND RESEARCH INSTITUTES   (United States)

^d Departments of Biostatistics and Epidemiology and Outcomes Research   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f SEATTLE CANCER CARE ALLIANCE   (United States)

^g BloodWorks Northwest   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLEEDING; CHEMOTHERAPY; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; HEMATOCRIT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; BIOLOGICAL MODEL; BLOOD CLOTTING TEST; CLINICAL TRIAL; HEMORRHAGE; METABOLISM; PATHOLOGY; THROMBOCYTE; TREATMENT OUTCOME;

ADULT; BLOOD COAGULATION TESTS; BLOOD PLATELETS; ERYTHROCYTE TRANSFUSION; FEMALE; FIBRINOGEN; HEMATOCRIT; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PARTIAL THROMBOPLASTIN TIME; PLATELET COUNT; PLATELET TRANSFUSION; TREATMENT OUTCOME;

EID: 85029223422     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-01-757930     Document Type: Article

References (17)

1. Friedmann AM, Sengul H, Lehmann H, Schwartz C, Goodman S. Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions. Transfus Med Rev. 2002;16(1):34-45.
2. Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010; 362(7):600-613.
3. Josephson CD, Granger S, Assmann SF, et al. Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia. Blood. 2012;120(4):748-760.
4. Heddle NM, Cook RJ, Tinmouth A, et al; SToP Study Investigators of the BEST Collaborative. A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood. 2009;113(7):1564-1573.
5. Wandt H, Schaefer-Eckart K, Wendelin K, et al; Study Alliance Leukemia. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet. 2012;380(9850): 1309-1316.
6. Stanworth SJ, Estcourt LJ, Powter G, et al; TOPPS Investigators. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med. 2013;368(19):1771-1780.
7. Goerge T, Ho-Tin-Noe B, Carbo C, et al. Inflammation induces hemorrhage in thrombocytopenia. Blood. 2008;111(10): 4958-4964.
8. Slichter SJ. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus Med Rev. 2004;18(3):153-167.
9. Webert K, Cook RJ, Sigouin CS, Rebulla P, Heddle NM. The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. Haematologica. 2006;91(11): 1530-1537.
10. Franchini M, Frattini F, Crestani S, Bonfanti C. Bleeding complications in patients with hematologic malignancies. Semin Thromb Hemost. 2013;39(1):94-100.
11. Valeri CR, Cassidy G, Pivacek LE, et al. Anemia-induced increase in the bleeding time: implications for treatment of nonsurgical blood loss. Transfusion. 2001;41(8):977-983.
12. Eugster M, Reinhart WH. The influence of the haematocrit on primary haemostasis in vitro. Thromb Haemost. 2005;94(6):1213-1218.
13. Ho CH. The hemostatic effect of packed red cell transfusion in patients with anemia. Transfusion. 1998;38(11-12):1011-1014.
14. Estcourt LJ, Stanworth SJ, Harrison P, et al. Prospective observational cohort study of the association between thromboelastometry, coagulation and platelet parameters and bleeding in patients with haematological malignancies- the ATHENA study. Br J Haematol. 2014;166(4): 581-591.
15. Blajchman MA, Bordin JO, Bardossy L, Heddle NM. The contribution of the haematocrit to thrombocytopenic bleeding in experimental animals. Br J Haematol. 1994;86(2):347-350.
16. Stanworth SJ, Hudson CL, Estcourt LJ, Johnson RJ, Wood EM; TOPPS study investigators. Risk of bleeding and use of platelet transfusions in patients with hematologic malignancies: recurrent event analysis. Haematologica. 2015;100(6): 740-747.
17. Schiffer CA. They took a mulligan and mostly got it right … the issue of prophylactic platelet transfusion for patients receiving autologous stem cell transplantation. Transfusion. 2014;54(10): 2372-2374.